to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Pfizer Inc. is testing a pilot of a virtual clinical trial program that could be of interest to medical device startups and young pharmaceutical and biotech companies.
The development of virtual world technology, in programs like Second Life and Habbo Hotel, has reached a point where these tools and concepts are beginning to change the way that businesses operate. A new Athena Alliance study contends that virtual worlds can become a critical...
Advice for life science entrepreneurs goes beyond the dollar value that could be placed on it. Watch this collection of videos with insights on a variety of topics of interest to life science entrepreneurs.
The 2010 Translational Medicine Alliance Forum, hosted by the Ewing Marion Kauffman Foundation, the Council for American Medical Innovation and Faster Cures, convened industry leaders to help facilitate a better understanding of effective models enabling and accelerating the progress of translating scientific research into patient treatment focusing on three key elements:
Venture capital investing in health IT is expected to increase, while investing in medical devices and biopharmaceuticals drops, according to a recent National Venture Capital Association survey. Read more about why VCs are favoring health IT companies.
Medical device startups are advised to respect the FDA and answer its questions, according to a panelist at a recent investing conference. Read more about this discussion.
Healthcare investing by venture capitalists dropped to its lowest level in five quarters, but the decrease follows a five-quarter high. Read more for details.
Venture capital investment by corporations in the healthcare sector fell in the first quarter, but that may improve since the Affordable Care Act was upheld. Read more about investments in the healthcare sector.
Hatteras Venture Partners, a venture capital firm, will invest $20 million to $30 million in helping companies through first-in-man and preclinical studies. The firm expects to invest in 10 to 15 companies in the healthcare business.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.